Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100659 · ClinicalTrials.gov registry record · Phase 3
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT00100659 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 114 participants.
The verdict
NCT00100659, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. The purpose of this study is also to determine whether PEG-2a in combination with RV or PEG-2a alone will result in a longer response rate in children with CHC.
Interventions
- DRUG Pegylated Interferon/ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2004-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100659
The ClinicalTrials.gov registry entry for NCT00100659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegylated Interferon/ribavirin is the first listed.
NCT00100659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100659 about?
NCT00100659 is a clinical study titled "PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C". The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. The purpose of this study is also to determine whether PEG-2a in combin...
What is the current status of trial NCT00100659?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2004-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00100659?
The interventions under investigation include: Pegylated Interferon/ribavirin (DRUG).
Who is sponsoring clinical trial NCT00100659?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.